VIA
LYEL icon

Vident Investment Advisory’s Lyell Immunopharma LYEL Stock Holding History

Vident Investment Advisory’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,056
Closed -$522K – 1287
2023
Q1 		$522K Sell
11,056
-79
-0.7% -$4.22K 0.02% 766
2022
Q4 		$773K Buy
11,135
+4,522
+68% +$449K 0.03% 556
2022
Q3 		$969K Sell
6,613
-708
-10% -$95.9K 0.03% 602
2022
Q2 		$955K Buy
+7,321
New +$748K 0.03% 637

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Vident Investment Advisory's LYEL Position: Q2 2023 in Review

Vident Investment Advisory sold out of Lyell Immunopharma (LYEL) in Q2 2023, closing a stake of 11,056 shares — an estimated $522K sold.

Vident Investment Advisory first reported a position in LYEL in Q2 2022 and held it in 4 quarters. The position peaked at $969K in Q3 2022. 99 funds tracked by Wall St. Rank hold LYEL as of Q2 2023.

  • Vident Investment Advisory reported no remaining Lyell Immunopharma position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 11,056 Lyell Immunopharma shares in Q2 2023, an estimated $522K.
  • Vident Investment Advisory first reported a position in Lyell Immunopharma in Q2 2022 and held it in 4 quarters.
  • Vident Investment Advisory's Lyell Immunopharma position peaked at $969K in Q3 2022.
  • 99 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.